MYC-SL is the most advanced of the programs and its lead compound is a first-in-class anticancer therapeutic, inhibiting a novel MYC synthetic lethal target. To support the oncogene-enabled ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, ...

This gives both parties access to what's known as a confidential data package containing sensitive information—raw data and chemical structures of lead compounds, for instance—that showcase a ...

today announced encouraging initial clinical data from the ongoing Phase I study of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft ...

A McMaster University researcher credited for discovering a chemical compound with “huge potential” in treating brain health ...

Munich, Germany – November 19, 2024 – Thermosome, a drug development company focused on targeted tumor therapies, today announced encouraging initial clinical data from the ongoing Phase I study of ...

They predicted that such compounds could be more effective against Cryptosporidium parasites and less toxic. The team identified two lead compounds that reduced the number of parasites in ...

CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ...